We raise adjusted EBITA by 4-6% for 2026E-28E, following the strong margin development in Q1, with a...
Physitrack’s Q1 2026 report confirms that the structural "SaaS-only" reset has successfully protecte...
Redeye comments on Hansa Biopharma's Q4 report. Revenues were SEK35m (SEK66m).
Redeye retains its positive view of Vitec following the Q1 report.
CDON posted a quarter with solid growth of 14% y/y.
* Underlying development looks promising * We raise our '26-'28 EBIT estimates by 3-1% * Share is tr...
* EBITA margin +20bp y-o-y supported by price adjustments * Warehouse move could offset opex inflati...
Careium reported its third consecutive quarter of organic growth, and we expect this momentum to con...
* Segment EBIT broadly in line with estimates * Margin-enhancing initiatives in Decommissioning payi...
Redeye presents its preview of RaySearch’s Q1 2026 results due on April 29.
Enviro has now formally responded to Infiniteria’s request to terminate the ongoing corporate recons...
Redeye gives a preview ahead of Sdiptech's Q1 2026 report, due on April 28.
CDON delivered Q1 total GMV of SEK 394m , 7% better than our estimate of SEK 369m growing 16% y/y, d...
Redeye considers Binero’s Q1 trading update mixed, with positive signs from the underlying repositio...
* Sales SEK 226m (flat y-o-y, +2% vs. ABGSCe) * EBIT SEK 12m, 23% below ABGSCe on higher corporate c...
DT’s Q1 figures matched estimates as EBITA improved by EUR 1m y/y to EUR 2.
Physitrack’s Q1 2026 report landed close to our overall expectations, maintaining the stable and pro...
Vitrolife's Q1 report came in largely in line with consensus showing organic growth of 5% in local c...
Careium reported 6% y/y sales growth in Q1, leading to sales in line with SEBe.
Redeye provides its first take on Hansa Biopharma's Q1 report.